EveliQure Biotechnologies

What EveliQure Biotechnologies does

EveliQure Biotechnologies GmbH is a privately held, clinical-stage biotechnology company headquartered at the Campus Vienna Biocenter in Vienna, Austria, founded in 2012 (per firmographic data; the company_history timeline records consortium activity beginning in 2019). The company's flagship product is ShigETEC, an orally administered, drinkable live attenuated vaccine that targets both Shigella and enterotoxigenic Escherichia coli (ETEC), two of the leading causes of diarrhoeal disease worldwide. The vaccine is built on a proprietary platform using a genetically engineered, non-invasive Shigella strain with four distinct modifications: deletion of the LPS O-antigen (exposing conserved minor antigens for serotype-independent broad protection), inactivation of the type III secretion system (rendering the strain non-invasive), inactivation of a putative enterotoxin (improving safety), and transposition of an essential gene to the invasion plasmid (stabilising heterologous antigen expression and preventing reversion). The strain additionally expresses a tandem LTB-ST toxoid fusion protein, providing neutralising antibodies against ETEC toxins. This architecture enables dual-pathogen coverage in a single oral dose and is positioned as a platform for further heterologous antigen expression.

The company's go-to-market strategy is dual-track: a traveller's diarrhoea market pursued through traditional pharmaceutical commercial channels, and an endemic LMIC paediatric market pursued through partnerships and public health channels. Commercialisation of the paediatric indication is anchored by a March 2026 strategic collaboration and licence agreement with Serum Institute of India, the world's largest vaccine manufacturer by dose volume, which provides global development, manufacturing, and commercialisation capacity. Clinical development is supported by the SHIGETECVAX consortium (European Vaccine Initiative, EveliQure, University of Gothenburg, icddr,b, and PATH) under an €8.6M EU Horizon 2020 grant, and a $20.6M NIAID contract funding Phase 2 development. ShigETEC is currently in Phase 2b, with first participants dosed in July 2025. The company is pre-revenue, with a 1-10 employee headcount, and is funded through a combination of EU, US, and Austrian public grants, Wellcome Trust support, and private investment from Arax Capital Partners and undisclosed private individuals.

Leadership combines deep vaccine development expertise: CEO Gábor Somogyi (MD, MBA) brings multi-stage business management experience; co-founder and CSO Tamás Henics (MD, PhD) leads the scientific platform; CMO Frank Malinoski (MD, PhD) provides 20+ years of vaccine development, regulatory, and post-licensure experience; and co-founder Eszter Nagy serves as President and Chair of the Board. The company has received the FFG Success Story recognition (2019) for the SHIGETECVAX project, and regulatory milestones include FDA approval of a Phase 2 human challenge study. No products are commercialised; revenue is not publicly disclosed.

Name

EveliQure Biotechnologies

Legal name

Eveliqure Biotechnologies GmbH

Website

https://eveliqure.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

EveliQure Biotechnologies is a Vienna-based, pre-revenue clinical-stage biotech developing ShigETEC, an oral live attenuated vaccine targeting both Shigella and ETEC for travellers and paediatric populations in endemic LMIC markets, currently in Phase 2b trials.

Ownership category

akta.pro rank

Product category

Vaccines

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

Keywords

• Live attenuated vaccines
• Diarrhoeal disease prevention
• Shigella vaccine development
• Enterotoxigenic E coli vaccine
• Oral vaccine platform

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Vaccine product sales (traveller's market): Revenue from sale of orally administered ShigETEC vaccine to travellers visiting endemic regions. Estimated market value of >€1B at peak for the traveller's diarrhoea market.
2. Vaccine product sales (LMIC endemic market): Revenue from sale of low-cost, drinkable ShigETEC vaccine for children and populations in low- and middle-income countries through public health channels and partnerships.
3. Licensing and partnership revenue: Revenue from strategic licensing agreements such as the collaboration with Serum Institute of India for development, manufacturing and commercialisation of ShigETEC for paediatric populations.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

EveliQure develops ShigETEC, an orally administered live attenuated vaccine that combines protection against Shigella and enterotoxigenic Escherichia coli (ETEC) in a single drinkable dose for both international travellers and paediatric populations in low- and middle-income countries. The vaccine is built on a proprietary platform using a genetically engineered, non-invasive Shigella strain with targeted mutations and heterologous antigen expression to deliver broad serotype-independent protection.

Product overview

EveliQure Biotechnologies is a biotech company developing novel vaccines for the prevention of diarrhoeal diseases. The company's primary offering is the ShigETEC vaccine, an orally administered live attenuated vaccine based on a proprietary platform using a genetically engineered Shigella strain. ShigETEC targets both Shigella and ETEC pathogens, addressing needs for travellers and populations in endemic low- and middle-income countries. The technology platform is designed for heterologous expression of diarrheal antigens, enabling potential expansion to additional pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

• ShigETEC Orally administered, live attenuated vaccine candidate that targets Shigella and enterotoxigenic Escherichia coli (ETEC) in a single drinkable dose, providing broad serotype-independent protection. Developed for international travellers and paediatric populations in low- and middle-income countries; currently in Phase 2b clinical development with Phase 2b dosing initiated in July 2025.

Quantifiable outcome

• No currently licensed vaccines exist for Shigella or ETEC diarrhoea - representing a significant unmet medical need
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and major.

• Serum Institute of IndiacoreStrategic or Co-development Partner · 20 March 2026Strategic collaboration for development, manufacturing and commercialisation of anti-diarrhoeal vaccines targeting global health pathogens. The partnership includes Eveliqure's proprietary vaccine program ShigETEC, aiming to reduce morbidity and mortality from diarrheal diseases in children, especially in low-income countries.
• SHIGETECVAX ConsortiumcoreStrategic or Co-development Partner · 1 January 2019World-leading vaccine consortium including European Vaccine Initiative (consortium leader), Eveliqure Biotechnologies, University of Gothenburg, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) and PATH. Received €8.6M EU Horizon 2020 grant for manufacture, formulation, Phase 1 safety and immunogenicity studies in Europe and Bangladesh.
• European Vaccine InitiativecoreStrategic or Co-development PartnerConsortium leader for SHIGETECVAX project. A partnership of world-leading vaccine organisations working on the development of ShigETEC vaccine.
• PATHmajorStrategic or Co-development PartnerSHIGETECVAX consortium partner, a global health organization focused on accelerating health equity through the development of effective and affordable vaccines.
• icddr,b (International Centre for Diarrhoeal Disease Research Bangladesh)majorStrategic or Co-development PartnerSHIGETECVAX consortium partner conducting Phase 1 safety and immunogenicity studies in Bangladesh, providing access to endemic population for clinical trials.
• University of GothenburgmajorStrategic or Co-development PartnerSHIGETECVAX consortium partner contributing to vaccine research and development expertise.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Inventprise: Clinical-stage vaccine developer with novel conjugate vaccine platforms targeting infectious diseases in LMICs. Comparable as a private, clinical-stage vaccine biotech targeting paediatric infectious disease in similar geographies.
• Vaxart: Clinical-stage biotech developing oral recombinant vaccines using a different platform (adenoviral vector) but focused on oral mucosal immunisation for enteric and other indications. Comparable in clinical stage and oral vaccine approach.
• Prokarium: UK-based clinical-stage biotech developing oral live-attenuated bacterial vaccines, including for enteric indications. Comparable platform philosophy (live bacterial vectors, oral delivery) and clinical stage to EveliQure.

Others

• PATH: Global health non-profit that develops and delivers vaccines for LMICs and is a SHIGETECVAX consortium partner. Relevant as an ecosystem enabler and an adjacent organisation working on the same Shigella/ETEC indication, though not a commercial competitor.
• Sanofi Pasteur:
• Serum Institute of India: World's largest vaccine manufacturer by doses and EveliQure's strategic partner for paediatric commercialisation of ShigETEC. Listed as a peer because of its direct role in the same Shigella/ETEC indication via the licence agreement, even though it is a partner rather than a competitor.

Direct peers

• Bharat Biotech: India-based vaccine manufacturer with active Shigella and enteric disease vaccine programs. Directly comparable as a developer of vaccines for paediatric diarrhoea in LMIC markets and a potential competitor for Serum Institute partnership share.
• LimmaTech Biologics: Swiss clinical-stage biotech developing vaccines against Shigella and other enteric pathogens, including combination approaches. Closest direct competitor in the Shigella vaccine space and the most directly comparable to EveliQure in target indication, clinical stage, and platform philosophy.
• Hilleman Laboratories: Singapore-based non-profit biotech with a focus on affordable vaccines for LMICs, including Shigella and ETEC candidates. Comparable mission (affordable enteric vaccines for low-resource settings) and Shigella/ETEC overlap.

Broad incumbents

• GSK (GlaxoSmithKline): One of the world's largest vaccine manufacturers with a traveller's health portfolio and historical interest in enteric vaccines. A broad incumbent whose eventual entry into the Shigella/ETEC space represents a key competitive threat to EveliQure.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eveliqure-biotechnologies/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EveliQure Biotechnologies